ACADIA PHARMACEUTICALS INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
ACADIA PHARMACEUTICALS INC. (ACAD) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $21.99 per share for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-28.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2024-02-28
- ACADIA PHARMACEUTICALS INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $21.99, a 3.51% decline from fiscal 2022.
- ACADIA PHARMACEUTICALS INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $22.79, a 47.75% decline from fiscal 2021.
- ACADIA PHARMACEUTICALS INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2021 was $43.62, a 0.37% decline from fiscal 2020.
- ACADIA PHARMACEUTICALS INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2020 was $43.78, a 55.14% increase from fiscal 2019.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|
| 2023-12-31 | $21.99 10-K · filed 2024-02-28 |
| 2022-12-31 | $22.79 10-K · filed 2023-02-28 |
| 2021-12-31 | $43.62 10-K · filed 2022-03-01 |
| 2020-12-31 | $43.78 10-K · filed 2021-02-25 |
| 2019-12-31 | $28.22 10-K · filed 2020-02-27 |
| 2018-12-31 | $19.24 10-K · filed 2019-02-27 |
| 2017-12-31 | $34.73 10-K · filed 2018-02-27 |
| 2016-12-31 | $26.98 10-K · filed 2017-02-28 |
| 2015-12-31 | $35.73 10-K · filed 2016-02-29 |
| 2014-12-31 | $25.32 10-K · filed 2015-02-26 |
| 2013-12-31 | $16.68 10-K · filed 2014-02-27 |
| 2012-12-31 | $1.93 10-K · filed 2013-03-12 |
| 2011-12-31 | $1.61 10-K · filed 2013-03-12 |
| 2010-12-31 | $1.44 10-K · filed 2013-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |